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Different biological aspects have to be considered when estimating 
the effect of radiotherapy on oligometastases: 
1) In contrast to current systemic treatments, radiotherapy has a high 
potential to inactivate cancer stem cells that are able to cause tu-
mour recurrences. In limited disease stages or, in some cancers, 
limited metastases stages, this is the basis of the curative potential of 
radiotherapy and also of complete inactivation of macroscopic metas-
tases. 
2) Size of the metastases is predictive for in-field-control. This corre-
lation exists in primary tumours as well as in metastases and reflects 
the impact of the higher number of cancer stem cells to be inacti-
vated in larger tumours and maybe also higher impact of other resis-
tance factors like hypoxia. 
3) Metastases develop through vascular spread of tumour cells, i.e. 
oligometastases always bear a high risk of later development of 
further metastases. The time to further disease Progression appears to 
be longest with a longer time interval between treatment of the 
primary tumour and development of oligometastases. While this is 
known for a long time, approaches to biologically characterize tu-
mours with low versus high potential for multi- or oligometastatic 
spread are only recently developed. 
4) Single or oligometastases are often treated using hypofractionated-
accelerated radiation treatment schedules, i.e. applying high doses 
per fraction and higher doses per week as compared to conventionally 
fractionated radiotherapy schedules. These schedules lead to a higher 
biological efficacy in the tumour, but also in irradiated normal organs. 
Thus, for application of high radiation doses, from biological reasons 
the use of high precision radiotherapy techniques is mandatory to take 
advantage from the volume-effects in normal tissues that can com-
pensate for the disadvantage of the high doses per fraction. 
The talk will give an overview on biological considerations for high-
dose radiotherapy of oligometastases and on open questions for 
further improvement of treatment. 
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Two models of circulating tumor cell (CTC) dynamics have been 
proposed to explain the phenomenon of tumor ’self-seeding’, whereby 
CTCs repopulate the primary tumor and accelerate growth: Primary 
Seeding, where cells from a primary tumor shed into the vasculature 
and return back to the primary themselves; and Secondary Seeding, 
where cells from the primary first colonize a secondary tissue which 
then sheds cells into the vasculature returning to the primary. The-
setwo models are difficult to distinguish experimentally, yet the 
differences between them is of great importance to both our under-
standing of the metastatic process and also for designing methods of 
intervention. Therefore we developed a mathematical model to test 
the relative likelihood of these two phenomena and show that Sec-
ondary Seeding is several orders of magnitude more likely than Prima-
ry seeding. We suggest how this difference could effect tumor evolu-
tion, progression and therapy and several possible methods of experi-
mental validation.  
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The role of positron emission tomography (PET) in radiation oncology 
continues to expand beyond the realm of preliminary diagnosis, where 
FDG PET has directly impacted disease staging in more than 30 % of 
cancer patients. Radiation oncology clinicians and researchers seek to 
incorporate PET more objectively into radiotherapy (RT) planning and 
therapeutic response assessment by leveraging its high sensitivity, 
tracer specificity, and capacity for absolute quantification. As PET 
evolves from a qualitative diagnostic tool to a quantitative theragnos-
tic tool, a growing number of clinical trials are evaluating the efficacy 
of personalized and adaptive RT regimens based on the spatiotempor-
al dynamics of heterogeneous PET uptake. 
However, complex quantitative tasks require the estimation and 
mitigation of many PET uncertainties. They arise from physical, 
technical, and biological factors that impact PET lesion signal (con-
trast) relative to noise, system spatial resolution,and reproducibility. 
This talk will review uncertainties that determine confidence intervals 
within which we can trust PET in the context of RT target definition 
and RT response assessment. In particular, physical uncertainties 
arising from the image formation process, technical uncertainties 
from pre- and post-imaging processes, and biological uncertainties 
from patient-specific tracer kinetics and therapy-induced dynamics 
will be presented. 
The level of trust in PET can be linked to the incorporation of uncer-
tainties into quantification processes. For example, test-retest studies 
can establish achievable degrees of precision when assessing longitu-
dinal changes in PET metrics. While some uncertainties are mitigated 
through standardization of imaging procedures within and between 
institutions, others pose formidable challenges that require innovative 
technologies and methodologies. Such challenges motivate the need 
for improved PET quantification and seamless integration into RT 
planning through multidisciplinary collaboration. 
 
  
Example workflow of PET quantification tasks in radiation oncolo-
gy. From tumor biology at the cellular scale to PET-based target 
definition and therapy response assessment at the image voxel scale, 
quantitative tasks carry uncertainties that must be estimated and 
mitigated. This talk will focus on uncertainties in Steps 1 and 2 in the 
context of their impact on downstream components.  
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PET is a functional and molecular imaging modality allowing to meas-
ure (biological) tumor characteristics quantitatively. The most com-
monly used parameter to quantify tumor tracer uptake is the so-called 
maximum standardized uptake value (SUVmax). Yet, various other 
parameters may be of interest. Metabolically active tumor volume 
(MATV), total tumor burden (sum of MATV over all lesions) or total 
lesion glycolysis (TLG, product of MATV and SUV) have shown value as 
predictive or prognostic factor. Beyond measuring glucose consump-
tion with 18F-FDG there is increased interest in the use of other trac-
ers and/or labeled drugs. Proliferation measured with 18F-FLT or 
hypoxia measured with e.g. 18F-AZA can be of particular interest in a 
radiotherapy setting. Specific imaging procedure optimizations may be 
required when using non-FDG PET tracers. In addition, use of simpli-
fied (static) image procedures and data analysis methods may need to 
be validated against full kinetic analysis to determine use of e.g. SUV 
as appropriate surrogate for the physiological parameter of interest. 
Full kinetic analysis can then be helpful to determine which simplified 
quantitative measure is providing the most accurate and robust 
results. For example, tumor to blood ratios may be more suitable than 
SUV measures and SUV normalized by body weight may be suboptimal 
compared to other normalizations, such as body surface area, depend-
ing on the biodistribution of the tracer. 
All quantitative PET measures, however, depend largely on the way 
PET images are collected, reconstructed and analyzed. Moreover, new 
image reconstruction technologies, that include resolution recovery, 
can improved image resolution and contrast recovery, but at the same 
time suffer from increased upward bias when PET images are quanti-
fied using the maximum standardized uptake value. Consequently, 
when implementing new PET imaging technologies one should also 
adapt data analysis procedures in order to obtain and maintain robust 
quantitative data. 
When quantitative PET studies are performed as part of multicenter 
studies it is not only essential to optimize the PET imaging and data 
analysis procedure for the specific question to be addressed, but also 
to make sure that studies are performed in a standardized manner and 
that all scanner performances are harmonized to a common standard. 
There are various organizations that offer scanner validation or accre-
ditation (QC) programs. Most of these programs recognize the need 
not only to verify the basic calibration and uniformity of the PET 
